Meeting
2016 Palliative and Supportive Care in Oncology Symposium
Rolapitant for the prevention of nausea in patients receiving moderately or highly emetogenic chemotherapy.
Authors
Rudolph M. Navari
Indiana University School of Medicine South Bend, Cancer Control Program, World Health Organization, South Bend, IN
Rudolph M. Navari, Cindy K Nagy, Sujata Arora, Daniel Powers, Rebecca Anne Clark-Snow
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Biologic Basis of Symptoms and Treatment Toxicities,Psycho-oncology,End-of-Life Care,Survivorship,Management/Prevention of Symptoms and Treatment Toxicities,Psychosocial and Spiritual Care,Communication in Advanced Cancer
Sub Track
Treatment toxicity
Clinical Trial Registration Number
NCT01500226, NCT01499849, NCT01500213
Citation
J Clin Oncol 34, 2016 (suppl 26S; abstr 224)
DOI
10.1200/jco.2016.34.26_suppl.224
Abstract #
224
Poster Bd #
H14
Abstract Disclosures
Similar Posters
Poster
2015 Palliative and Supportive Care in Oncology Symposium
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in non–anthracycline/cyclophosphamide (AC)-based moderately emetogenic therapy (MEC).
First Author: Daniel Powers
Poster
2015 ASCO Annual Meeting
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC).
First Author: Paul Joseph Hesketh
Poster
2014 ASCO Annual Meeting
Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC).
First Author: Laszlo Urban
Poster
2015 ASCO Annual Meeting
Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).
First Author: Martin Chasen